Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04267445Unknown

Evaluate the Safety and Effectiveness of Using Echogenic Embolic Agent for Embolization of Prostate Artery for Treatment of Men With BPH (PAE CEUS)

Role: collaborator

NCT03427671Not ApplicableCompleted

OCL 500 Treatment of Women With Symptomatic Uterine Fibroids

Role: lead

NCT02410018Not ApplicableCompleted

Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata

Role: lead

NCT02509975Not ApplicableCompleted

Safety and Efficacy of OCL 503 in Prostate Artery Embolization

Role: lead

All 4 trials loaded